Maze Therapeutics, Inc. (MAZE) vs Nutex Health Inc. (NUTX)
Maze Therapeutics, Inc. and Nutex Health Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — MAZE vs NUTX, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Maze Therapeutics, Inc. (MAZE) | Nutex Health Inc. (NUTX) | |
|---|---|---|
| Market cap | $1.4B | $1.0B |
| Revenue (latest FY) | $0 | $875.26M |
| Net income (latest FY) | $-131.12M | $70.79M |
| Revenue growth (5y CAGR) | — | 26.1% |
| Net margin | — | 8.1% |
| Return on equity | -36.9% | 21.5% |
| P/E ratio | — | 10.1 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 5 |
| Positive free cash flow | No | Yes |
Performance — MAZE vs NUTX
Total returns from monthly split- and dividend-adjusted closes; 52-week range from the latest quote. Past performance is not a prediction.
| Maze Therapeutics, Inc. (MAZE) | Nutex Health Inc. (NUTX) | |
|---|---|---|
| 1-year return | 100.5% | 11.3% |
| 3-year return | — | 119.0% |
| 5-year return | — | — |
| 10-year return | — | — |
| 52-week range | $9.83–$53.65 | $77.21–$193.07 |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full MAZE vs NUTX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open MAZE's full financials → Open NUTX's full financials →More comparisons
Frequently asked questions
Which is bigger, MAZE or NUTX?
Maze Therapeutics, Inc. is larger by market capitalization — $1.4B versus $1.0B.
Which grows faster, MAZE or NUTX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.